1. Background {#sec1}
=============

Acute respiratory distress syndrome (ARDS) is a common acute critical illness. The main pathophysiological changes are reduced lung volume, reduced lung compliance, and severe ventilation/blood flow imbalance, with a mortality rate of up to 40% \[[@B1], [@B2]\], and the main treatment strategy is to actively treat the primary disease, mechanical ventilation, oxygen therapy, and restrictive fluid management \[[@B3]\]. Many clinical applications of glucocorticoids, nitric oxide inhalation, pulmonary surfactants, and symptomatic treatments have achieved certain effects in animal experiments but have not achieved satisfactory clinical results and may have more serious clinical side effects \[[@B4]--[@B6]\]. Traditional Chinese medicine (TCM) has a unique understanding on the pathogenesis of ARDS. It is believed that the main reason for the occurrence and development of ARDS is that the normal physiological function of the lung is weakened and the pathological factors are increased. Related studies have shown that TCM has obvious effects in reducing ARDS/ALI lung tissue inflammation, reducing mortality, and improving prognosis. TCM compound has multiple targets. Compared with a single blocker, it has better clinical advantages in treating diseases, and has broad application prospects for the prevention and treatment of ARDS \[[@B7]--[@B9]\].

As an important intervention due to its significant preventive and therapeutic effects, TCM treatment included novel coronavirus pneumonia diagnosis and treatment plan in China\'s fight against the epidemic of COVID-19 \[[@B10]\]. Novel coronavirus pneumonia is significantly improved in the treatment of integrated traditional Chinese and Western medicine in improving clinical symptoms and reducing hospitalization time \[[@B11]\]. At the same time, TCM treatment plays an important role in reducing the development of sepsis, ARDS, and patient mortality \[[@B12]\]. In the previous meta-analysis study, we found that the combination of traditional Chinese and Western medicine in the treatment of ARDS has significant advantages in improving the mortality rate and reducing the time of mechanical ventilation compared with simple support treatment \[[@B13]\].

YQHYJD is the clinical experience decoction of Professor Du Huaitang from Dongzhimen Hospital of Beijing University of Chinese medicine. It is composed of 8 traditional Chinese medicines, which are commonly used in the clinical practice of traditional Chinese medicine, namely, *Radix Astragali* (the dried roots of *Astragalus membranaceus (*Fisch*.)* Bunge, also named as Huangqi in Chinese), *Panax notoginseng* (the dried roots of *Panax notoginseng (*Burk.*) F. H. Chen*, also named as Sanqi in Chinese), *Flos Lonicerae* (the dried flowers of *Lonicera japonica* Thunb., also named as Jinyinhua in Chinese), *Radix Scutellariae* (the dried roots of *Scutellaria baicalensis Georgi*, also named as Huangqin in Chinese), *Radix Paeoniae Rubra* (the dried roots of *Paeonia lactiflora* Pall. or *Paeonia veitchii* Lynch*.,* also named as Chishao in Chinese), *Fructus Aurantii Immaturus* (the dried fruits of *Citrus aurantium L*. or *Citrus sinensis* Osbeck*.,* also named as Zhishi in Chinese), *Cortex Mori* (the dried root barks of *Morus alba L*., also named as Sangbaipi in Chinese), *Semen Descurainiae* (the dried seeds of *Lepidium apetalum* Willd. or *Descurainia sophia (*L.) Webb. ex Prantl, also named as Tinglizi in Chinese).

Eight traditional Chinese medicines in YQHYJD are used with reference to the traditional efficacy of TCM in the "Pharmacopoeia of the People\'s Republic of China" \[[@B14]\]. Pharmacological studies have shown that some of the active ingredients in these traditional Chinese medicines have anti-ALI/ARDS effects, such as *Astragaloside* IV in *Radix Astragali* which can alleviate LPS-induced acute lung injury by inhibiting the activation of NF-*κ*B pathway and the expression of inflammatory genes \[[@B15]\]. *Astragalus polysaccharide* inhibits the expression of ICAM-1 and VCAM-1 in TNF-*α* treated human vascular endothelial cells by blocking NF-*κ*B activation \[[@B16]\]. PNS (*Panax notoginseng saponins*) is very effective in promoting blood circulation to dissipate blood stasis and in improving blood circulation \[[@B17]\]; at the same time, ginsenoside Rb1 in *Panax notoginseng* can reduce the expression of ICAM-1 and ICAM-1, improve the connection between pulmonary microvascular endothelial cells, and reduce lung injury \[[@B18]\]. Baicalein, main component of *Radix Scutellariae*, can prevent LPS-induced acute lung injury in rats \[[@B19]\]. lx-1-mediated endothelial oxidative damage was attenuated by baicalein regulating AMPK/PKC/NADPH oxidase/NF-*κ*B signaling pathway. Therefore, baicalein reduced the formation and dysfunction of SOD-1 ROS induced by NADPH oxidase \[[@B20]\]. *Flos Lonicerae*\'s active ingredient quercetin negatively regulates TLR4 signaling induced by lipopolysaccharide through Tollip expression and quercetin and quercitrin protect against cytokine induced injuries in RINm5F *β*-cells via the mitochondrial pathway and NF-*κ*B signaling; these active compounds of *Flos Lonicerae* have been shown to exhibit a variety of modulatory effects on the inflammation process by reducing the induction of proinflammatory cytokines \[[@B21], [@B22]\]. *Radix Paeoniae Rubra* is able to reduce heat and cool blood, disperse stasis, and relieve pain. It was observed that total paeony glycoside (effective component of *Radix Paeoniae Rubra*) can inhibit apoptosis and oxidative stress by significantly reducing the phosphorylation level of PI3K and Akt and then regulate hemodynamics \[[@B23]\]. Hesperidin, neohesperidin, and neohesperidin dihydrochalcone are the main effective components in *Fructus Aurantii Immaturus;* they have been proved to have the properties of antioxidant \[[@B24]\], anti-inflammatory \[[@B25]\], vasopressive, and antiplatelet \[[@B26]\], which may play a preventive and therapeutic effect in the process of ALI. Research shows that morusin (the effective component of *cortex mori*) treatment led to decreased levels of proinflammatory cytokines such as interleukin, IL-6, and IL-1*β*, and TNF-*α* and increased level of anti-inflammatory IL-10 in mice lung tissue. Morusin relieves mycoplasma pneumonia via the inhibition of the activation of Wnt/*β*-catenin and NF-*κ*B pathways \[[@B27]\]. *Semen Descurainiae* extract administration significantly reduced mucus production, inflammatory cell infiltration into airways, and eosinophil activation by reducing the expression of type 2 cytokines and inhibiting differentiation and activation of Th2 cells \[[@B28]\]. In addition, many effective components in these traditional Chinese medicines have been proved to have the functions of anti-inflammation, antioxidation, reducing cell damage, inhibiting cell apoptosis, and oxidative stress, which play an important role in the treatment of ALI/ARDS.

According to the clinical observation for many years, we found that the series prescription of YQHYJD had a significant effect on the treatment of critical respiratory system diseases \[[@B29]\], and our previous work \[[@B30]--[@B33]\] shows that YQHYJD has protective effects on lung injury caused by endotoxin in ARDS rats. The compound can reduce alveolar collapse, reduce inflammatory cell exudation, and at the same time reduce pulmonary edema and improve lung permeability. And it can reduce serum tumor necrosis factor-*α* (TNF-*α*), interleukin-1*β* (IL-1*β*), interleukin-6 (IL-6), interleukin-8 (IL-8), and other proinflammatory factors, reduce NF-*κ*B p50, p65, mitogen-activated protein kinase p38, and other inflammatory proteins expressions, and increase anti-inflammatory factors I*κ*B*α*, interleukin-4 (IL-4), and interleukin-10 (IL-10) expression. At the same time, the group confirmed the intervention effect of the compound on ARDS at the level of proteomics, but the mechanism of action was not clear.

The concept of network pharmacology was firstly systematically elaborated by the British pharmacologist Andrew L. Hopkins in 2007. The "disease-gene-target-drug" interaction network is the research object, and a systematic analysis of the interaction relationship between drugs and the body is conducted to discover new drugs and explore the research methods of drug efficacy and mechanism of action \[[@B34]\]. Using online pharmacology combined with experimental verification, it was found that the therapeutic effect of Dengzhan Xixin Injection on ischemic stroke is mainly through the intervention of NF-kappa B signal, TNF signal, and PI3K-Akt signal, and then it exerts the dual role of anti-inflammatory and antiplatelet effect \[[@B35]\]. In the network pharmacology study of Huanglian Jiedu decoction for the treatment of "internal fire," it was found that the mechanism of action of this prescription mainly includes anti-OS/NS, anti-inflammatory, and anti-infection, mainly achieved by regulating PI3K-AKT, MAPK, VEGF, and calcium signals conductive pathway \[[@B36]\]. TCM compound has the characteristics of multiple component compatibility and multiple target systems, which is consistent with the research ideas of the integrity and dynamics of network pharmacology. Network pharmacology is emerging in the field of TCM research \[[@B37]\].

In this work, based on the network pharmacology research strategy, we integrate bioinformatics methods such as network construction and analysis, pathways, and target prediction to study the relevant molecular networks of YQHYJD in ARDS rats. Combined with animal experiments, the prediction results are validated and the mechanism of the compound intervention in ARDS is explored. The work in this paper can provide valuable references for the further quality control, product development, and clinical application of the compound. [Figure 1](#fig1){ref-type="fig"} depicts the flowchart of our study.

2. Methods {#sec2}
==========

2.1. Materials and Chemicals {#sec2.1}
----------------------------

LPS *Escherichia coli* and PBS solutions were purchased from Sigma Company in the United States; chloral hydrate, paraformaldehyde, absolute ethanol, xylene, methanol, and so on were purchased from Beijing Chemical Industry Group Co., Ltd. Hematoxylin and eosin dyes were purchased from Beijing Zhongshan Jinqiao Biotechnology Co., Ltd. Liquid paraffin, RIPA lysate, 30% polyacrylamide solution-bisacrylamide, 4 × separation gel buffer, 4 × concentrated gel buffer, 10 × electrophoresis solution, 10 × electrophoresis solution, and so on were purchased from Beijing Solibao Technology Co., Ltd. BCA protein quantitative analysis kit, protease inhibitor (100x), 10% ammonium persulfate solution, TEMED, skimmed milk powder, and TBST were purchased from Beijing Pulailai Gene Technology Co., Ltd. Anti-AKT1 antibody and anti-KRAS/HRAS/NRAS antibody were purchased from Abbot (Shanghai) Trading Co., Ltd. Primary antibody dilutions were purchased from Shanghai Biyuntian Biotechnology Co., Ltd. Goat anti-rabbit IgG/HRP was purchased from Beijing Baierdi Biotechnology Co., Ltd. Chemiluminescence liquid was purchased from GE Company in the United States.

2.2. Animals {#sec2.2}
------------

A total of 30 clean male SD rats were selected, aging 8 weeks old and weighing 190--210 g (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.). They were fed in the Barrier Laboratory of Experimental Animal Center, Dongzhimen Hospital, Beijing University of Chinese Medicine (6 rats per cage, temperature 22--24°C, humidity 50--70%, free drinking water, and solid particle feed). The experiment was approved by the Experimental Animal Welfare and Ethics Committee of Dongzhimen Hospital of Beijing University of Chinese Medicine. The international experimental pharmacological principles were strict when handling animals.

2.3. Source and Preparation of YQHYJD {#sec2.3}
-------------------------------------

The composition of YQHYJD used for research was *Radix Astragali* 30 g, *Panax Notoginseng* 10 g, *Flos Lonicerae* 15 g, *Radix Scutellariae* 10 g, fried *Fructus Aurantii Immaturus* 12 g, *Radix Paeoniae Rubra* 15 g, *Semen Descurainiae* 15 g, and *Cortex Mori* 15 g; the medicinal materials used in the research are from Bozhou Yonggang Decoction Pieces Factory Co., Ltd. and the formulation was a TCM extract. Use 10 times the quality of water to decoct the traditional Chinese medicine for 2 times, each time for 30 minutes. The decoction obtained from the two decoctions was mixed, centrifuged, concentrated to 1.22*g* crude drug/ml, and finally stored at 4°C before use, which was produced and provided by Institute of Chinese Materia Medica, Chinese Academy of Chinese Medical Sciences (Batch No.:20170320).

2.4. Establishment and Analysis of ARDS-Related Molecular Network of Potential Targets of Chinese Materia Medica in YQHYJD {#sec2.4}
--------------------------------------------------------------------------------------------------------------------------

TCMIP (V1.0) \[[@B38]\] database of Chinese herbal medicines is based on the *Chinese Pharmacopoeia* (2015 edition), which contains more than 400 commonly used Chinese herbal medicines. In the Chinese medicine information setting interface, the 8 Chinese herbs contained in YQHYJD were searched and collected separately. For all chemical components, all drug targets with a similarity score ≥0.8 were selected as potential targets for YQHYJD at the Chinese medicine target prediction interface.

TCMIP disease/symptom target database integrates biological database information such as Drugbank \[[@B39]\], KEGG \[[@B40]\], OMIM \[[@B41]\], TTD \[[@B42]\], and HPO \[[@B43]\]. Through the TCMIP disease target information data retrieval interface, the English abbreviation "ARDS" was searched as a keyword to obtain information about the disease targets currently known to treat ARDS.

2.5. Collection of PPI Information {#sec2.5}
----------------------------------

By integrating the above potential drug targets and ARDS disease targets and inputting into the STRING database (V11.0) \[[@B44]\], the PPI network was calculated and generated. Adjusting the network parameters, the "confidence" was used as the confidence of the edges in the network to set the minimum interaction score as 0.9 (highest confidence). The ARDS-related molecular network information of the potential target of Chinese herbs contained in YQHYJD was calculated and saved.

The PPI network data obtained in the above steps were input into Cytoscape software (V 3.5.1) \[[@B45]\] for network visualization and analysis and established "the potential target-ARDS related molecular network of Chinese herbs contained in YQHYJD." By calculating the PPI network topology characteristic value, the median of degree, closeness centrality, and betweenness centrality as the card values, and the nodes that meet the three card values at the same time were selected as the key network nodes.

The key nodes of the above network were input into the DAVID database (V6.8) \[[@B46]\], and related pathways and biological function enrichment analysis were performed. The target pathways and related target genes were analyzed combined with the literature, and the key targets for the compound intervention in ARDS were screened. Animals\' experiments were designed for verification.

2.6. *In Vivo* Animal Experiment {#sec2.6}
--------------------------------

The speculated mechanism of YQHYJD in the treatment of ARDS by a network pharmacological method was then verified by polypharmacology using an ARDS model.

2.7. Experimental Scheme {#sec2.7}
------------------------

A total of 30 SD rats were randomly divided into 5 groups of a normal control group (NC), a model control group (MC), a low-dose group (LDG), a medium-dose group (MDG), and a high-dose group (HDG), with 6 rats in each group. The rats were weighed and recorded, with adaptive feeding for 1 week. Weighing and recording before each experiment. The dosage was calculated according to the adult\'s weight of 60 kg. The dose calculated by the rats and adults based on a factor of 6.25 times was the Chinese medicine dose. The low was 0.5 times as dose of the medium, and the high was 2 times as dose of the medium. Chinese medicine extract was prepared into 6.1 g/kg/d, 12.2 g/kg/d, and 24.4 g/kg/d (refer to the weight of the crude medicine) Chinese medicine decoction, which were equivalent to clinical equivalent doses of 0.5, 1, and 2 times, respectively. After the end of the adaptive feeding, Chinese medicine was administered to prevent the stomach. The normal group and the model group were given 1 mL/100 g/d of distilled water for 7 consecutive days. Each group had normal drinking water. The Chinese medicine solution was prepared with distilled water, and the medicinal solution and distilled water were stored in a refrigerator at 4°C and heated in a warm water bath before the operation of gastric administration.

Inflammatory ARDS rat model was established by tail vein injection of lipopolysaccharides (LPS). Previous research of the research group proved that the modeling method was stable and effective \[[@B30], [@B47]--[@B49]\]. After gavage for 6  hours on day 7, the rats were weighed and recorded. The model group and each Chinese medicine group were injected with LPS (2 mg/kg body weight) in the tail vein to establish the ARDS model caused by infection. The normal control group was injected with normal saline (2 mg/kg body weight) in the tail vein. Materials were obtained under anesthesia at 16 hours after modeling, and rats were deprived of water for 8 hours before the materials were obtained. Rats were anesthetized by intraperitoneal injection of 1.5% pentobarbital sodium solution (2 ml/kg) and exposed to chest cavity. After sampling, continue to inject appropriate pentobarbital sodium solution until respiratory arrest, and then cervical dislocation, confirm euthanasia. The whole lungs were removed from the level of tracheal cartilage and quickly placed in a cryogenic dish filled with PBS. The sterile equipment was used to take the right lung tissue of the rat under sterile conditions, and placed the upper 1/3 of the lung tissue in a fixed solution (4% paraformaldehyde solution) for pathological examination, and the remaining 2/3 of the lung tissue was stored in a refrigerator at 80°C for western blot to detect the expression level of the target protein.

2.8. Observation of Lung Injury {#sec2.8}
-------------------------------

The pathological changes of the lungs, including color, degree of edema, and degree of congestion, were observed with naked eye and recorded with a digital camera. The right lung tissue specimen was taken and paraffin sections were made through fixing, washing, dehydrating, clearing, immersing in wax, and embedding. After staining with hematoxylin and eosin (HE), it was observed under an optical microscope.

Western blot method was used to detect the expression level of potential target protein. Lung tissue was subjected to protein extraction and protein concentration was determined using BCA method. The target protein expression level was determined by SDS-PAGE electrophoresis, membrane transfer, protein-antibody reaction, chemiluminescence, and development.

2.9. Statistical Analysis {#sec2.9}
-------------------------

In this study, SPSS 21.0 software was used for statistical analysis. Each group of data was expressed as mean ± standard deviation $\left( {\overline{x} \pm s} \right)$. When variances were uniform, one-way analysis of variance was used to test for significance of differences. When variances were uneven, rank sum test was used. *P* \< 0.05 was the standard with significant difference. Graphpad Prism 7 software and Adobe Photoshop CS6 version software were used to make data chart.

3. Results {#sec3}
==========

3.1. Network Pharmacology-Based Analysis {#sec3.1}
----------------------------------------

### 3.1.1. Prediction of Potential Targets of YQHYJD {#sec3.1.1}

The TCMIP database of Chinese herbal medicines was used to search the 8 Chinese herbal ingredients contained in YQHYJD, and a total of 369 Chinese herbal ingredients were collected, of which *Radix Astragali, Panax Notoginseng, Flos Lonicerae, Radix Scutellariae, Radix Paeoniae Rubra, Fructus Aurantii Immaturus, Cortex Mori,* and *Semen Descurainiae* were collected with the number of 29, 95, 47, 54, 20, 49, 54, and 21 (Supplementary [Figure 1](#supplementary-material-1){ref-type="supplementary-material"}). The predicted target numbers and the common targets among drugs were shown in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}. The analysis of common target of drugs means the correlation analysis of different Chinese medicines acting on the same target, which means that there is mutual synergy or antagonism between Chinese herbs. The more the common targets are, the stronger the synergy or antagonism will be. A total of 278 potential targets were obtained for the compound (Supplementary [Figure 2](#supplementary-material-1){ref-type="supplementary-material"}).

The above-mentioned drug targets were analyzed by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. It was found that the drug targets involved in biological functions mainly include oxidation-reduction process, mitochondrial electron transport, mitochondrial respiratory chain complex I assembly, membrane depolarization during action potential, aldehyde dehydrogenase (NAD) activity, voltage-gated sodium channel activity, NF-kappaB signaling, and response to oxidative stress (Supplementary [Figure 3](#supplementary-material-1){ref-type="supplementary-material"}); drug target participation pathways mainly include oxidative phosphorylation, HIF- 1 signaling pathway, mTOR signaling pathway, apoptosis, VEGF signaling pathway, gap junction, AMPK signaling pathway, NF-kappa B signaling pathway, FoxO signaling pathway, Ras signaling pathway, and MAPK signaling pathway (Supplementary [Figure 4](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.1.2. Network Establishment and Analysis of YQHYJD Intervening in ARDS {#sec3.1.2}

In this study, a total of 322 pieces of target information for ARDS diseases were obtained (Supplementary [Figure 5](#supplementary-material-1){ref-type="supplementary-material"}). Integrating drug-related targets and disease-related targets, it was found that there were 40 targets in the 2 types of target profiles ([Figure 2](#fig2){ref-type="fig"}). They were NSDHL, CASK, DYRK1A, GCK, ALDH3A2, PIK3R1, AKT1, B4GALT1, HSD17B10, EHHADH, CHUK, MAPK1, YWHAE, PTPN11, GAA, KRAS, PIK3R2, INS, ATP5A1, TUBG1, GNAS, DLD, GCDH, UQCRC2, CPT2, GDI1, HNF1A, PPARG, ABCC9, RPS6KA3, PDHA1, MAPT, P4HB, GRIN2B, ACSL4, ACOX1, VCP, ABCC8, TNFSF11, and PTS. The existence of common targets indicated that there is overlap between the potential drug target and the disease treatment target that has been supported by evidence, further indicating that YQHYJD has sufficient scientific connotation to prevent and treat ARDS.

The PPI data calculated by STRING were input into the Cytoscape software to establish the "potential target -ARDS-related molecular network of Chinese medicine contained in YQHYJD." By analyzing and calculating the network characteristic values, 61 key network nodes were selected ([Table 3](#tab3){ref-type="table"}). After visualization, [Figure 3](#fig3){ref-type="fig"} was obtained.

The key targets of the above network in the DAVID database were analyzed to obtain the related pathways and biological function information ([Figure 4](#fig4){ref-type="fig"}) and sort them by importance ([Table 4](#tab4){ref-type="table"} only listed entries with *P* value \<9.0 × 10^−6^). Key target functions mainly involve ErbB signaling pathway, VEGF signaling pathway, focal adhesion, FoxO signaling pathway, influenza A, MAPK signaling pathway, regulation of actin cytoskeleton, Toll-like receptor signaling pathway, insulin signaling pathway, adherens junction, mTOR signaling pathway, gap junction, Ras protein signal transduction, positive regulation of ERK1 and ERK2 cascade, and so on. The correlation between ErbB signaling pathway with the highest *P* value and key targets was analyzed, and 14 key targets were found to be enriched in ErbB signaling pathway, as shown in [Figure 5](#fig5){ref-type="fig"}.

By analyzing the upstream and downstream of the ErbB signaling pathway, it was found that key targets were mainly located on the downstream PI3K-AKT signal axis and MAPK signal axis. Combined with our previous research results, it was believed that YQHYJD might play an interventional role in ARDS by regulating these 2 signal axes. In order to verify the network analysis and prediction results, animal experiments were designed for verification.

3.2. Evaluation and Analysis of YQHYJD on ARDS *in Vivo* {#sec3.2}
--------------------------------------------------------

### 3.2.1. Observation and Evaluation of Lung Injury {#sec3.2.1}

During the onset of ARDS, the occurrence of explosive inflammatory reactions led to pathological changes in lung tissue damage. Therefore, it is of great significance to reduce inflammation damage and protect lung tissue function in terms of treatment. As shown in [Figure 6](#fig6){ref-type="fig"}, after HE staining, microscopic observation showed that the normal group had clear lung tissue structure, complete alveoli, normal alveolar septum, no edema, no exudation of alveolar cavity and lung tissue, and no congestion and inflammatory cell infiltration. In the model group, the lung tissue structure was damaged. Part of the alveolar atrophy collapsed. The alveolar cavity was reduced. The alveolar wall was thickened, and alveolar, interstitial, and bronchi were exuded and tissue edema, inflammatory cell infiltration, and red blood cells were seen in some alveoli and bronchi. Pulmonary capillaries congestion and edema were visible; the degree of lung tissue damage in the low-dose Chinese medicine group was lighter than that in the model group, with a small amount of collapsed alveoli and a small amount of fluid exudation in the alveolar cavity and lung tissue. Some alveolar walls thickened, and alveolar capillaries slightly congested, with edema; the lung tissue of the medium dose group was lighter than the lower dose group, with mild lung tissue edema. No obvious fluid exudation in the alveolar cavity and no alveolar capillary congestion and edema were observed. The degree of lung tissue damage in the compound high-dose group was lighter than that in the model group. A small amount of collapsed alveoli, alveolar, and interstitial edema can be seen, and alveolar capillaries can be seen with slight blood edema.

### 3.2.2. Effects of YQHYJD on AKT1 and KRAS/HRAS/NRAS Expression in ARDS Rats {#sec3.2.2}

Each dose group can reduce the expression levels of AKT1 and KRAS/HRAS/NRAS in lung tissue of ARDS rats to varying degrees. The compound high-dose group significantly reduced the expression of AKT1 (*P* \< 0.01), while there was a dose-dependent inhibition of AKT1 overexpression; each dose group of the compound significantly reduced the expression of KRAS/HRAS/NRAS (*P* \< 0.001) ([Figure 7](#fig7){ref-type="fig"}).

4. Discussion {#sec4}
=============

ARDS is a clinically critical illness characterized by progressive respiratory distress, refractory hypoxemia, and nonuniform exudation of pulmonary imaging \[[@B1]\]. At present, there are many opinions on ARDS that are based on experiments. Most of the opinions based on experimental evidence believe that the explosive inflammatory response caused by various pathogenic factors in the course of ARDS is an important link leading to severe exudation and even bleeding of lung tissue, which leads to severe impairment or loss of lung function \[[@B50], [@B51]\]. ARDS has a high clinical mortality rate, and finding effective treatment options has become the focus of current research. The Yiqi Huayu Jiedu decoction selected in this study has been proven in the basic research conducted by the research group in the past to effectively reduce the degree of lung tissue damage in ARDS rats and reduce the expression levels of proinflammatory factors and inflammation-related proteins. Our purpose in this study is to systematically analyze and predict the target of the compound intervention in ARDS and to verify it in combination with *in vivo* experiments, to provide a reliable basis for the further research of the compound.

According to the enrichment analysis of the core target pathways of the ARDS network that YQHYJD interferes, the core target pathways include ErbB signaling pathway, VEGF signaling pathway, focal adhesion, FoxO signaling pathway, influenza A, MAPK signaling pathway, Toll-like receptor signaling pathway, insulin signaling pathway, adherens junction, mTOR signaling pathway, gap junction, Ras protein signal transduction, and positive regulation of ERK1 and ERK2 cascade ([Table 4](#tab4){ref-type="table"}). These interactions are related to the pathological mechanism of ARDS. The decrease of VEGF in the lung injury model of cigarette exposure plus LPS inhalation is related to the mechanism that induces ARDS due to increased alveolar capillary permeability, exacerbation of inflammation, epithelial damage, and endothelial dysfunction \[[@B52]\]. The regulation of VEGF signaling pathway is also related to complications such as ALI/ARDS due to lobectomy \[[@B53]\]. Focal adhesions in ARDS and other diseases, through the process of intercellular dynamic signal transduction, cause increased endothelial permeability and inflammatory reactions such as edema \[[@B54]\]. FoxO signaling pathway is involved in the pathological process of pulmonary vascular endothelial cells that reduce tight junctions in ARDS, leading to exudative edema \[[@B55]\]. In the ARDS model caused by influenza, macrophage activation can induce direct apoptosis of alveolar epithelial cells \[[@B56]\]. C3G can play an important anti-inflammatory and antioxidant role by inhibiting the NF-*κ*B pathway and MAPK pathway and improve LPS-induced ARDS/ALI \[[@B57]\]. In ARDS, pro-mRNA splicing of TLR signaling genes has been associated with proinflammatory changes \[[@B58]\]. Insulin stimulates alveolar fluid clearance and reduces ALI pulmonary edema by upregulating the expression of *α*-ENaC, *β*-ENaC, and *γ*-ENaC on the surface of alveolar cells \[[@B59]\]. The mTOR signaling pathway is involved in protecting the endothelial cell barrier, improving vascular endothelial permeability, and interfering with ARDS progression \[[@B60]\]. Gap junction plays an important role in the permeability of the alveolar capillary barrier. Decreasing connexins such as VE-cadherin and Caluin 5 will lead to increased permeability of the ALI/ARDS vascular barrier, which in turn will promote edema formation and respiratory failure \[[@B61]\]. Blocking Ras-associated protein Rab10 can lead to reduced TLR4 expression, reduced production of inflammatory cytokines and interferons, and reduced lung injury \[[@B62]\]. ERK1/2 inhibitors can significantly reduce lung injury in A779 pretreated ACE2 overexpressing rats, thereby reducing LPS-induced ARDS \[[@B63]\]. According to the enrichment results, YQHYJD mainly regulates inflammatory response, vascular endothelial barrier function, and coagulation and fibrinolytic function when intervening in ARDS.

Based on the above analysis, YQHYJD can interfere with ARDS by targeting different genes through multiple signaling pathways. Therefore, we evaluated the predictions through *in vivo* studies. As shown in [Figure 6](#fig6){ref-type="fig"}, during the course of ARDS, the compound can protect lung tissues to varying degrees. Each dose group can effectively enhance the ability of rats to resist endotoxin attack. The pathological morphology of lung tissue of ARDS rats in each dose group is better than the model group. There are varying degrees of relief. As shown in [Figure 7](#fig7){ref-type="fig"}, the compound middle-dose group can effectively reduce the expression of AKT1, while the high-dose group has a more significant downregulation level. At the same time, the compound has a tendency to inhibit AKT1 overexpression in a dose-dependent manner. Each compound group can significantly reduce KRAS/HRAS/NRAS expression level.

The full name of AKT1 is RAC-alpha serine/threonine-protein kinase, which is involved in regulating cell metabolism, proliferation, cell survival, growth, and angiogenesis through serine and/or threonine phosphorylation of a series of downstream substrates. It is an important downstream signal protein of the PI3K-AKT pathway \[[@B64]\]. AKT1 and its involved PI3K-AKT signaling pathway, mTOR signaling pathway, and VEGF signaling pathway play important roles in the pathological process of regulating ALI/ARDS pulmonary vascular endothelial permeability \[[@B65]\]. In the experiment of edaravone intervention for lung injury, the downregulation of PI3K/AKT pathway protein can reduce the peroxidation reaction and DNA damage, and it can improve the lung injury *in vivo* and *in vitro* experiments \[[@B66]\]. In the experiments of *Staphylococcus aureus*-induced lung injury, the increase in p-AKT expression in the PI3K/AKT cascade was positively correlated with the degree of cell damage \[[@B67]\]. Ligustrazine can improve inflammation and fibrosis in lung tissue of ALIrats, inhibit PI3K/AKT/mTOR pathway activation, reduce p-PI3K/PI3K, p-AKT/AKT, and p-mTOR/mTOR ratios, and reduce LPS-induced ALI\[[@B68]\]. As shown in [Figure 5](#fig5){ref-type="fig"}, AKT1 is an important functional protein on the PI3K/AKT signaling pathway and is closely related to the downstream mTOR signaling pathway and VEGF signaling pathway that regulate vascular endothelial function. Therefore, we believe that the role of YQHYJD which reduces lung tissue edema in ARDS rats may be related to reducing AKT1 expression, affecting downstream signaling pathways, and then regulating vascular endothelial permeability.

KRAS, HRAS, and NRAS are different structural monomers of GTPase Ras protein, and they are activation proteins of MAPK transduction pathway. Studies have found that inhibiting the MAPK cascade can reduce lung tissue damage, and its mechanism may be related to inhibiting oxidative stress and apoptosis and blocking inflammatory responses \[[@B69]--[@B71]\]. Blocking the phosphorylation of JNK and p38 and inhibiting the MAPK signal can reduce lung permeability and reduce ALI caused by sepsis \[[@B72]\]. The blockage of p38 MAPK signaling pathway caused macrophages to change from inflammatory apoptosis to noninflammatory apoptosis and alleviated the excessive inflammatory response in ALI mice \[[@B73]\]. Studies have found that Xuebijing Injection can alleviate the effects of paraquat by downregulating the p38MAPK-NF-*κ*B inflammatory signaling pathway and blocking the expression of p-p38MAPK, NF-*κ*B65, HIF-1*α*, p-I*κ*B-*α*, and TGF-*β*1 ALI \[[@B74]\]. At the same time, the NF-kappaB signaling pathway is involved in the pathogenesis of ARDS alveolar hypercoagulability and fibrinolysis inhibition \[[@B75]\]. We also found in previous work that YQHYJD can inhibit inflammation-related proteins such as NF-*κ*Bp50, MAPK P38, p65, and the expression of TNF-*α*, IL-1*β*, IL-6, IL-8, and other proinflammatory factors, which plays a protective role in the lung tissue of ARDS rats \[[@B30]--[@B33]\]. As shown in [Figure 5](#fig5){ref-type="fig"}, Ras protein (KRAS/HRAS/NRAS) is located upstream of the MAPK signaling pathway. Inhibiting this site protein can block the MAPK cascade and affect downstream NF-*κ*B signaling pathway activation, thereby reducing the release of inflammatory proteins and inflammatory factors, which is in line with the results of our previous research. Therefore, we believe that YQHYJD might block the MAPK signaling pathway by inhibiting the expression of KRAS/HRAS/NRAS, thereby reducing lung tissue inflammation.

In this study, each dose group of YQHYJD downregulated the expressions of PI3K-AKT pathway downstream protein AKT1 and MAPK pathway activating protein KRAS/NRAS/HRAS to different extents, which played a role in the intervention of ARDS. The predictions are consistent.

5. Conclusion {#sec5}
=============

In short, a systematic study of YQHYJD was conducted through predictive analysis and *in vivo* experiments. The experimental results are consistent with those predicted by network analysis. This study not only evaluated the anti-inflammatory effects of YQHYJD in intervening ARDS, but also proposed that YQHYJD regulates vascular endothelial function and anticoagulant function, which deserves further study.
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YQHYJD:

:   Yiqi Huayu Jiedu

ARDS:

:   Acute respiratory distress syndrome

ALI:

:   Acute lung injury

TCM:

:   Traditional Chinese medicine

NF-*κ*B:

:   Nuclear factor kappa-B

TNF-*α*:

:   Tumor necrosis factor-*α*

LPS:

:   Lipopolysaccharide

IL:

:   Interleukin

TCMIP:

:   Integrative pharmacology-based research platform of traditional Chinese medicine

OMIM:

:   Online Mendelian Inheritance in Man

TTD:

:   Therapeutic target database

HPO:

:   Human phenotype ontology

PPI:

:   Protein-protein interaction

GO:

:   Gene ontology

KEGG:

:   Kyoto Encyclopedia of Genes and Genomes

DAVID:

:   Database for annotation, visualization, and integrated discovery

NC:

:   Normal control

MC:

:   Model control

LDG:

:   Low-dose group

MDG:

:   Medium-dose group

HDG:

:   High-dose group.
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###### 

There are 5 supplementary figures in the submitted supplementary materials. Supplementary Figure 1: Yiqi Huayu Jiedu decoction ingredients, including Radix Astragali ingredients, Panax Notoginseng ingredients, Flos Lonicerae ingredients, Radix Scutellariae ingredients, Radix Paeoniae Rubra ingredients, Fructus Aurantii Immaturus ingredients, Cortex Mori ingredients, and Semen Descurainiae ingredients. Supplementary Figure 2: potential target information of Yiqi Huayu Jiedu decoction. Supplementary Figure 3: GO enrichment analysis of drug prediction target. Supplementary Figure 4: KEGG enrichment analysis of drug prediction target. Supplementary Figure 5: the target information for ARDS diseases. A graphical abstract is also provided.

###### 

Click here for additional data file.

![The flowchart of network pharmacology-based strategy for deciphering the mechanisms of YQHYJD acting on ARDS. YQHYJD, Yiqi Huayu Jiedu decoction; TCMIP, integrative pharmacology-based research platform of traditional Chinese medicine; OMIM, Online Mendelian Inheritance in Man; TTD, therapeutic target database; KEGG, Kyoto Encyclopedia of Genes and Genomes; PPI, protein-protein interaction.](ECAM2020-4782470.001){#fig1}

![The Venn diagram of the targets both in ARDS targets and YQHYJD targets. PDT, putative drug targets; KDT, known disease targets.](ECAM2020-4782470.002){#fig2}

![Construction of YQHYJD-ARDS PPI network. (a) Interactive PPI network of YQHYJD and ARDS with 497 nodes and 3969 edges. (b) First central network evaluation with a core subset of 149 nodes and 2950 edges based on the median degree of 12. (c) Second central network evaluation with a core subset of 61 nodes and 1100 edges based on ""Degree" \> 35, "betweenness centrality" \>0.002, "closeness centrality" \>0.56". (d) Network diagram of 61 core targets. White nodes, green nodes, and gray nodes stand for common targets, known disease targets, and putative drug targets, respectively.](ECAM2020-4782470.003){#fig3}

![DAVID enrichment analysis of the 61 core targets.](ECAM2020-4782470.004){#fig4}

![The anti-ARDS pathway of YQHYJD in KEGG. The red nodes represent the known disease targets, the yellow nodes represent the putative drug targets. The pink nodes represent the common targets, and the green nodes represent the targets in the pathway.](ECAM2020-4782470.005){#fig5}

![Comparison of pathological morphology of the lung tissue of the rat (×400): (a) NC group, (b) MC group, (c) low-dose group, (d) middle-dose group, and (e) high-dose group.](ECAM2020-4782470.006){#fig6}

![The effect of YQHYJD groups (LDG, 6.1 g/kg; MDG, 12.2 g/kg; HDG, 24.4 g/kg) on the expression of inflammation related protein in the lung of ARDS rats. (a) Expression of AKT1. (b) Expression of KRAS/HRAS/NRAS. All data was presented as mean ± SD (*n* = 5). ^\#^*P*, ^*∗*^*P*, and ^*∗∗*^*P* mean the *P* values are less than 0.05, 0.01, and 0.001, respectively, by contrast to model group.](ECAM2020-4782470.007){#fig7}

###### 

Basic information of TCM composition target of YQHYJD.

  Chinese Pinyin name   Latin name                     Number of components   Number of predicted targets
  --------------------- ------------------------------ ---------------------- -----------------------------
  Huang-qi              *Radix Astragali*              29                     412
  San-qi                *Panax Notoginseng*            95                     239
  Jin-yin-hua           *Flos Lonicerae*               47                     209
  Huang-qin             *Radix Scutellariae*           54                     242
  Chi-shao              *Radix Paeoniae Rubra*         20                     193
  Zhi-shi               *Fructus Aurantii Immaturus*   49                     131
  Sang-Bai-pi           *Cortex Mori*                  54                     148
  Ting-li-zi            *Semen Descurainiae*           21                     178
  Sum                   ---                            369                    1752

###### 

The common target among the components of YQHYJD.

  Drugs                                *Panax Notoginseng* (239)   *Cortex Mori* (148)   *Radix Astragali* (412)   *Radix Scutellariae* (242)   *Fructus Aurantii Immaturus* (131)   *Radix Paeoniae Rubra* (193)   *Flos Lonicerae* (209)   *Semen Descurainiae* (178)
  ------------------------------------ --------------------------- --------------------- ------------------------- ---------------------------- ------------------------------------ ------------------------------ ------------------------ ----------------------------
  *Panax Notoginseng* (239)            ---                         49                    150                       137                          35                                   71                             106                      91
  *Cortex Mori* (148)                  49                          ---                   118                       122                          106                                  103                            122                      106
  *Radix Astragali* (412)              150                         118                   ---                       216                          104                                  146                            167                      161
  *Radix Scutellariae* (242)           137                         122                   216                       ---                          105                                  150                            158                      159
  *Fructus Aurantii Immaturus* (131)   35                          106                   104                       105                          ---                                  110                            118                      105
  *Radix Paeoniae Rubra* (193)         71                          103                   146                       150                          110                                  ---                            145                      108
  *Flos Lonicerae* (209)               106                         122                   167                       158                          118                                  145                            ---                      114
  *Semen Descurainiae* (178)           91                          106                   161                       159                          105                                  108                            114                      ---

###### 

Information on 61 key hub targets.

  Uniprot ID   Gene symbol   Target type            Degree   Betweenness   Closeness
  ------------ ------------- ---------------------- -------- ------------- ------------
  P05771       PRKCB         Putative drug target   35       0.00264685    0.56704981
  P25786       PSMA1         Putative drug target   36       0.00300257    0.5648855
  P06400       RB1           Known disease target   37       0.00253187    0.57142857
  Q92769       HDAC2         Putative drug target   38       0.00336775    0.56923077
  P63208       SKP1          Putative drug target   38       0.00245534    0.57142857
  Q99460       PSMD1         Putative drug target   39       0.00248828    0.57364341
  O60566       BUB1B         Known disease target   41       0.00549867    0.56704981
  P62873       GNB1          Putative drug target   41       0.00718391    0.56923077
  P22681       CBL           Known disease target   42       0.00342413    0.578125
  P25963       NFKBIA        Putative drug target   42       0.00433339    0.578125
  P04150       NR3C1         Putative drug target   43       0.00468953    0.58498024
  P51692       STAT5B        Putative drug target   43       0.00325874    0.58039216
  O14818       PSMA7         Putative drug target   43       0.00316088    0.58039216
  Q05655       PRKCD         Putative drug target   44       0.00449992    0.58730159
  P31751       AKT2          Known disease target   44       0.00270419    0.58730159
  P61073       CXCR4         Putative drug target   45       0.00558369    0.58498024
  P37231       PPARG         Common target          45       0.00371233    0.58498024
  Q13485       SMAD4         Known disease target   47       0.00371397    0.58964143
  Q92793       CREBBP        Known disease target   47       0.00699241    0.592
  P60709       ACTB          Known disease target   48       0.00650353    0.59677419
  P63000       RAC1          Putative drug target   48       0.00516601    0.59677419
  Q14738       PPP2R5D       Known disease target   49       0.00893634    0.59677419
  P35570       IRS1          Putative drug target   49       0.00452074    0.59919028
  P17612       PRKACA        Putative drug target   50       0.01349606    0.60162602
  P11802       CDK4          Known disease target   50       0.00628716    0.60162602
  P11142       HSPA8         Putative drug target   50       0.01720136    0.60162602
  P06239       LCK           Putative drug target   53       0.00312328    0.6090535
  P00519       ABL1          Putative drug target   53       0.00590445    0.60655738
  Q16665       HIF1A         Putative drug target   53       0.00718986    0.6090535
  P06241       FYN           Putative drug target   53       0.00504871    0.6090535
  P10275       AR            Putative drug target   54       0.0067063     0.61157025
  P21359       NF1           Known disease target   54       0.00762371    0.6090535
  P04049       RAF1          Known disease target   55       0.00496974    0.61410788
  Q06124       PTPN11        Common target          56       0.00363149    0.61666667
  Q02750       MAP2K1        Known disease target   57       0.0043254     0.61924686
  P62714       PPP2CB        Putative drug target   57       0.01088017    0.61924686
  P19838       NFKB1         Putative drug target   57       0.00880836    0.61666667
  P61586       RHOA          Putative drug target   58       0.00571048    0.62184874
  P01100       FOS           Known disease target   58       0.00710084    0.61924686
  Q09472       EP300         Known disease target   59       0.0174571     0.62447257
  O60674       JAK2          Known disease target   60       0.00538805    0.62711864
  P01111       NRAS          Known disease target   62       0.00549342    0.63247863
  P46531       NOTCH1        Known disease target   63       0.00726887    0.63247863
  P27986       PIK3R1        Common target          65       0.00815513    0.64069264
  Q04206       RELA          Putative drug target   65       0.01465454    0.64069264
  P60953       CDC42         Putative drug target   69       0.01943588    0.65198238
  P05412       JUN           Putative drug target   69       0.01511756    0.65198238
  P30153       PPP2R1A       Known disease target   71       0.02557709    0.65777778
  P42336       PIK3CA        Known disease target   71       0.01292212    0.65777778
  P67775       PPP2CA        Putative drug target   73       0.0246169     0.66367713
  P01133       EGF           Known disease target   77       0.01462345    0.67579909
  P01308       INS           Common target          77       0.0175801     0.67579909
  P07900       HSP90AA1      Putative drug target   77       0.02388431    0.67579909
  P01116       KRAS          Common target          81       0.01319493    0.68837209
  P12931       SRC           Putative drug target   85       0.01745904    0.7014218
  P28482       MAPK1         Common target          86       0.02512912    0.7047619
  P60484       PTEN          Known disease target   87       0.0220011     0.70813397
  P01112       HRAS          Known disease target   87       0.01721804    0.70813397
  P35222       CTNNB1        Known disease target   91       0.02966048    0.72195122
  P31749       AKT1          Common target          95       0.03102752    0.73631841
  P04637       TP53          Putative drug target   105      0.05675909    0.77486911

###### 

Information on 15 pathways.

  Term ID            Pathway name                                   Count   *P* value
  ------------------ ---------------------------------------------- ------- ----------------
  hsa04012           ErbB signaling pathway                         16      5.10 × 10^−15^
  hsa04370           VEGF signaling pathway                         13      1.40 × 10^−12^
  hsa04510           Focal adhesion                                 18      2.00 × 10^−11^
  hsa04068           FoxO signaling pathway                         15      7.20 × 10^−11^
  hsa05164           Influenza A                                    15      1.80 × 10^−10^
  hsa04010           MAPK signaling pathway                         18      1.80 × 10^−10^
  hsa04810           Regulation of actin cytoskeleton               15      1.30 × 10^−8^
  hsa04620           Toll-like receptor signaling pathway           11      3.90 × 10^−8^
  hsa04910           Insulin signaling pathway                      12      8.70 × 10^−8^
  hsa04520           Adherens junction                              10      8.80 × 10^−8^
  hsa04931           Insulin resistance                             11      1.60 × 10^−7^
  hsa04150           mTOR signaling pathway                         8       1.60 × 10^−6^
  hsa04540           Gap junction                                   9       4.00 × 10^−6^
  GOTERM_BP_DIRECT   Ras protein signal transduction                5       7.30 × 10^−6^
  GOTERM_BP_DIRECT   Positive regulation of ERK1 and ERK2 cascade   7       9.00 × 10^−6^

[^1]: Guest Editor: Huu-Tung Nguyen
